glp 1 cancer risk GLP-1 Receptor Agonists in Breast Cancer: A New Frontier in Obesity and Prognosis Management Glucagon-like peptide 1 receptor agonists

Several GDF-15 agonists are undergoing early phase clinical trials including NNC0247-0829 and JNJ-9090/CIN-109

For instance, liraglutide (Victoza), dulaglutide (Trulicity), and subcutaneous semaglutide (Ozempic) have data supporting risk reduction of major adverse cardiovascular events as well as preserving kidney function in patients with T2DM.(2)(3)(4) Another benefit of GLP-1 and GIP/GLP-1 receptor agonists is significant weight loss, specifically seen with liraglutide, semaglutide, and tirzepatide, which are now available as FDA approved products for weight management with the brand names Saxenda, Wegovy, and Zepbond respectively.(5)(6)(7) While these products have great glycemic, weight, and cardiovascular outcomes, the benefits have resulted in some detrimental repercussions

For outcome: No limitation

Asab G, Zereffa EA, Teshome AS (2020) Synthesis of Silica-Coated Fe 3 O 4 Nanoparticles by Microemulsion Method: Characterization and Evaluation of Antimicrobial Activity